Dr. Lindsay Rosenwald has been the originator and chairman of the following companies that fall under the operating jurisdiction of the Paramount Group of Companies: Paramount BioSciences, a pharmaceutical development/health care investment firm that assists new biotechnology companies around the world. Paramount Corporate Development, a company that makes drug and corporate expansion possible for Paramounts portfolio companies. Paramount BioCapital, a FINRA-registered broker-dealer that raises money for Paramounts portfolio companies and has raised roughly $950,000,000 since its creation. Dr. Rosenwald is the President of the Rosenwald Foundation, a charitable group in New York which helps outstanding scientists in their continued works towards research and development in the advancement of biotechnology. The Rosenwald Foundation has also given millions to many exceptional educational institutions. Dr. Rosenwald is also apart of the Columbia-Presbyterian Health Sciences Advisory Counsel. The Columbia Presbyterian Health Sciences Advisory Council comes together twice yearly, giving the Award for Distinguished Service to those whose work has made a especially important impact on society's health and well-being.
Dr. Lindsay Rosenwald acquired his medical degree from Temple University School of Medicine in 1983, since then he has been committed to and vital in the creation and world-wide development of many public and private biotechnology and life-science companies. (Dr. Rosenwald also received a Bachelor of Science degree in finance from Pennsylvania State University in 1977. He has been a pioneer in biotechnology on Wall Street for over 20 years. Dr. Rosenwald was one of the first Physician Analysts on Wall Street in 1986. Using his skills in the medical and financial industries he formed Paramount Biocaptial in 1991. He is thought to be one of the world's most inventive and influential individuals in the history of the biotechnology industry.
Dr. Rosenwald's Paramount portfolio companies presently have dozens of compounds in clinical trials. Not long ago Arsenic Trioxide, a cancer drug to treat a form of fatal leukemia, and created by PolaRx BioPharmaceuticals, a portfolio institution of the Paramount Group, has been authorized for marketing only 30 months after the initial patient was given the drug in a clinical trial, setting a record for the biotechnology industry. Dr. Rosenwald also attained the record for the largest amount ever paid for a drug that hadn't completed clinical development. He also created Cougar Biotechnology which was sold in 2009 for close to $1 billion by Johnson and Johnson. The remarkable transaction was based on a drug that had finished phase 2 in clinical trials for prostate cancer but had not yet finished phase 3 in clinical trials. Dr. Rosenwald's companies has transformed the biotechnology industry.
Over the next 20 years the biotechnology field will expand rapidly. Dr. Rosenwald believes in satisfying the demand for safer and more effectual treatments with medical advancements discovered by his companies. Dr. Rosenwald discoveries within the Paramount Group of Companies will lead to better treatments of diseases, for instance cancer and heart disease. Dr. Lindsay Rosenwald believes that revolutionary technologies will be made by the smaller biotechnology and life-science companies, like the companies he has created within the Paramount Group of Companies. Under the authority of Dr. Rosenwald, the Paramount Group of Companies has been key to the development of a few select products, giving more attention to those products and securing their success in the biotechnological industry.
Dr. Lindsay A. Rosenwald has been a key pharmaceutical and biotechnology investor for over 10 years. His many achievements and knowledge originated within broad spectrum of his pharmaceutical and biomedical business and investment experience, which is comprised of investment banking, venture capital, merchant banking and asset management. Dr. Rosenwald has assisted in the success of many careers for MDs, PhDs, MBAs, attorneys and related professionals by leading and skillfully operating the Paramount Group of Companies.
